EVX V1
Alternative Names: Cytomegalovirus vaccine - Evaxion Biotech; EVX-V1Latest Information Update: 18 Nov 2024
Price :
$50 *
At a glance
- Originator Evaxion Biotech
- Developer Evaxion Biotech; ExpreS2ion Biotechnologies
- Class Cytomegalovirus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cytomegalovirus infections
Most Recent Events
- 12 Nov 2024 Preclinical trials in Cytomegalovirus infections (Prevention) in Denmark (unspecified route)
- 12 Nov 2024 Pharmacodynamic data from a preclinical study in Cytomegalovirus infection released by Evaxion Biotech
- 06 Dec 2022 Evaxion Biotech and ExpreS2ion Biotechnologies agree to co-develop EVX V1 for Cytomegalovirus infections prevention